Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis.
Mammalian target of rapamycin (mTOR) inhibitors modulate signaling pathways involved in cell cycle progression, and recent phase II trials demonstrate activity in patients with endometrial cancer. Our objective was to examine the effects of combination therapy with rapamycin and paclitaxel in endometrial cancer cell lines. Paclitaxel inhibited proliferation in a dose-dependent manner in both cell lines with IC(50) values of 0.1-0.5 nM and 1-5 nM for Ishikawa and ECC-1 cells, respectively. To assess synergy of paclitaxel and rapamycin, the combination index (CI) was calculated by the method of Chou and Talalay. Simultaneous exposure of cells to various doses of paclitaxel in combination with rapamycin (1 nM) resulted in a significant synergistic anti-proliferative effect (CI <1, range 0.131-0.920). Rapamycin alone did not induce apoptosis, but combined treatment with paclitaxel increased apoptosis over that of paclitaxel alone. Treatment with rapamycin and paclitaxel resulted in decreased phosphorylation of S6 and 4E-BP1, two critical downstream targets of the mTOR pathway. Rapamycin decreased hTERT mRNA expression by real-time RT-PCR while paclitaxel alone had no effect on telomerase activity. Paclitaxel increased polymerization and acetylation of tubulin, and rapamycin appeared to enhance this effect. Thus, in conclusion, we demonstrate that rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation, induction of apoptosis and potentially increased polymerization and acetylation of tubulin. This suggests that the combination of rapamycin and paclitaxel may be a promising effective targeted therapy for endometrial cancer.
Shafer
Aaron
A
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, North Carolina 27599-7572, USA.
Zhou
Chunxiao
C
Gehrig
Paola A
PA
Boggess
John F
JF
Bae-Jump
Victoria L
VL
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D015153:Blotting, Western; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D016889:Endometrial Neoplasms / Q000473:pathology*; D005260:Female; D006801:Humans; D020128:Inhibitory Concentration 50; D017239:Paclitaxel / Q000008:administration & dosage; D011494:Protein Kinases / Q000187:drug effects / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*; D020123:Sirolimus / Q000008:administration & dosage; D058570:TOR Serine-Threonine Kinases; D019098:Telomerase / Q000096:biosynthesis / Q000187:drug effects; D014404:Tubulin / Q000096:biosynthesis / Q000187:drug effects
D014404:Tubulin; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D019098:Telomerase; D017239:Paclitaxel; D020123:Sirolimus
Cell. 2005 Mar 25;120(6):747-59
15797377
Br J Cancer. 2006 Jan 30;94(2):195-9
16404421
EMBO J. 1997 Jun 16;16(12):3693-704
9218810
Mol Cancer Ther. 2003 Aug;2(8):789-95
12939469
J Immunol. 1996 Jul 15;157(2):656-60
8752914
Cancer. 2009 Sep 1;115(17):3887-96
19484784
Semin Cancer Biol. 2000 Dec;10(6):399-406
11170862
Genes Dev. 2001 Apr 1;15(7):807-26
11297505
Expert Opin Investig Drugs. 2008 Dec;17(12):1947-54
19012509
Mol Cancer Ther. 2004 Dec;3(12):1605-13
15634654
Clin Cancer Res. 2007 Jul 15;13(14):4261-70
17634556
Curr Opin Cell Biol. 1998 Feb;10(1):123-30
9484604
Endocr Relat Cancer. 2003 Mar;10(1):23-42
12653669
Oncogene. 2004 Jul 29;23(34):5781-91
15208671
Drug Resist Updat. 2008 Jun;11(3):63-76
18440854
Crit Rev Oncol Hematol. 2006 Jun;58(3):242-56
16436330
Apoptosis. 2003 Oct;8(5):413-50
12975575
Gynecol Oncol. 2006 Mar;100(3):487-94
16249016
Gynecol Oncol. 1998 Feb;68(2):145-9
9514809
Endocr Relat Cancer. 2007 Sep;14(3):839-45
17914112
Oncol Rep. 1999 Jan-Feb;6(1):39-44
9864398
Clin Cancer Res. 2000 Feb;6(2):452-9
10690523
Curr Opin Immunol. 1998 Jun;10(3):330-6
9638370
Cancer Cell. 2007 Jul;12(1):9-22
17613433
Adv Enzyme Regul. 1984;22:27-55
6382953
Br J Cancer. 2004 Oct 18;91(8):1420-4
15365568
Oncogene. 2001 Sep 27;20(43):6172-80
11593425
Clin Cancer Res. 2004 Oct 15;10(20):7031-42
15501983
Gynecol Oncol. 2006 Apr;101(1):158-67
16434086
Mol Cancer. 2005 Jul 20;4(1):25
16033649
EMBO J. 1994 Mar 1;13(5):1205-15
8131750
Oncogene. 2003 Jan 30;22(4):484-97
12555062
Anticancer Res. 2004 Nov-Dec;24(6):3843-50
15736420
Gynecol Oncol. 2004 Sep;94(3):785-95
15350374
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
Mol Cancer Ther. 2002 Sep;1(11):937-41
12481415
Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1330-40
17626998
Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9666-70
11493700
Pharmacol Res. 2004 Dec;50(6):545-9
15501691
Cancer Res. 2001 Feb 15;61(4):1527-32
11245461
Cancer Res. 2003 Feb 1;63(3):579-85
12566299
Eur J Cancer. 2006 May;42(7):934-47
16540312
Gynecol Oncol. 1997 Jan;64(1):171-5
8995569
Cancer Chemother Pharmacol. 2008 Jul;62(2):305-13
17912526